Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation

Chun Ming Tsai, Chao Hua Chiu, Kao Ting Chang, Jen-Ting (Tina) Chen, Chun Liang Lai, Yuh Min Chen, Shih Yin Hsiao

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

INTRODUCTIONS:: Although randomized clinical trials showed no benefit from combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with standard chemotherapy for advanced non-small-cell lung cancer (NSCLC), better results might be obtained by combining EGFR-TKI with individual agents that are substrates for the adenosine triphosphate binding cassette transporters (ABCTs) because EGFR-TKIs can inhibit their efflux. The combination effects deserved to be further examined in vitro. METHODS:: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. The effects of drug combinations, identified by the values of mean combination index (mCIs), were correlated with the expression levels of ABCTs. Dose-versus-log-response curves were analyzed to further evaluate the possible mechanisms of drug interactions. RESULTS:: Synergistic gefitinib/AMTA interactions were observed in the tested cell lines. The synergism was more robust in the four lines overexpressing de novo or acquired P-glycoprotein (Pgp; individual mCIs range, 0.484-0.859; all p values were < 0.05), or in 12 cell lines exhibiting no sensitizing EGFR mutations (group mCIs for gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/vinorelbine were 0.869, 0.82, and 0.853, respectively. All p values were < 0.02). The synergism could be observed in cells expressing nearly undetectable Pgp and other ABCTs tested in this study. The combination of gefitinib/gemcitabine was additive (mCI = 1.027). CONCLUSIONS:: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. Gefitinib could enhance AMTA effects through mechanisms not restricted to Pgp blockage.

Original languageEnglish (US)
Pages (from-to)1218-1227
Number of pages10
JournalJournal of Thoracic Oncology
Volume7
Issue number8
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
docetaxel
gemcitabine
Protein-Tyrosine Kinases
Adenosine Triphosphate
Paclitaxel
Cell Line
gefitinib
P-Glycoprotein
Drug Combinations
Drug Interactions
Randomized Controlled Trials
Drug Therapy

Keywords

  • Antimicrotubule agent
  • Gefitinib
  • Nonsmall-cell lung cancer
  • P-glycoprotein
  • Synergism

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. / Tsai, Chun Ming; Chiu, Chao Hua; Chang, Kao Ting; Chen, Jen-Ting (Tina); Lai, Chun Liang; Chen, Yuh Min; Hsiao, Shih Yin.

In: Journal of Thoracic Oncology, Vol. 7, No. 8, 08.2012, p. 1218-1227.

Research output: Contribution to journalArticle

Tsai, Chun Ming ; Chiu, Chao Hua ; Chang, Kao Ting ; Chen, Jen-Ting (Tina) ; Lai, Chun Liang ; Chen, Yuh Min ; Hsiao, Shih Yin. / Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. In: Journal of Thoracic Oncology. 2012 ; Vol. 7, No. 8. pp. 1218-1227.
@article{b5a1de775a7b42809d9615ea27bde092,
title = "Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation",
abstract = "INTRODUCTIONS:: Although randomized clinical trials showed no benefit from combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with standard chemotherapy for advanced non-small-cell lung cancer (NSCLC), better results might be obtained by combining EGFR-TKI with individual agents that are substrates for the adenosine triphosphate binding cassette transporters (ABCTs) because EGFR-TKIs can inhibit their efflux. The combination effects deserved to be further examined in vitro. METHODS:: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. The effects of drug combinations, identified by the values of mean combination index (mCIs), were correlated with the expression levels of ABCTs. Dose-versus-log-response curves were analyzed to further evaluate the possible mechanisms of drug interactions. RESULTS:: Synergistic gefitinib/AMTA interactions were observed in the tested cell lines. The synergism was more robust in the four lines overexpressing de novo or acquired P-glycoprotein (Pgp; individual mCIs range, 0.484-0.859; all p values were < 0.05), or in 12 cell lines exhibiting no sensitizing EGFR mutations (group mCIs for gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/vinorelbine were 0.869, 0.82, and 0.853, respectively. All p values were < 0.02). The synergism could be observed in cells expressing nearly undetectable Pgp and other ABCTs tested in this study. The combination of gefitinib/gemcitabine was additive (mCI = 1.027). CONCLUSIONS:: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. Gefitinib could enhance AMTA effects through mechanisms not restricted to Pgp blockage.",
keywords = "Antimicrotubule agent, Gefitinib, Nonsmall-cell lung cancer, P-glycoprotein, Synergism",
author = "Tsai, {Chun Ming} and Chiu, {Chao Hua} and Chang, {Kao Ting} and Chen, {Jen-Ting (Tina)} and Lai, {Chun Liang} and Chen, {Yuh Min} and Hsiao, {Shih Yin}",
year = "2012",
month = "8",
doi = "10.1097/JTO.0b013e318258cf17",
language = "English (US)",
volume = "7",
pages = "1218--1227",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",

}

TY - JOUR

T1 - Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation

AU - Tsai, Chun Ming

AU - Chiu, Chao Hua

AU - Chang, Kao Ting

AU - Chen, Jen-Ting (Tina)

AU - Lai, Chun Liang

AU - Chen, Yuh Min

AU - Hsiao, Shih Yin

PY - 2012/8

Y1 - 2012/8

N2 - INTRODUCTIONS:: Although randomized clinical trials showed no benefit from combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with standard chemotherapy for advanced non-small-cell lung cancer (NSCLC), better results might be obtained by combining EGFR-TKI with individual agents that are substrates for the adenosine triphosphate binding cassette transporters (ABCTs) because EGFR-TKIs can inhibit their efflux. The combination effects deserved to be further examined in vitro. METHODS:: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. The effects of drug combinations, identified by the values of mean combination index (mCIs), were correlated with the expression levels of ABCTs. Dose-versus-log-response curves were analyzed to further evaluate the possible mechanisms of drug interactions. RESULTS:: Synergistic gefitinib/AMTA interactions were observed in the tested cell lines. The synergism was more robust in the four lines overexpressing de novo or acquired P-glycoprotein (Pgp; individual mCIs range, 0.484-0.859; all p values were < 0.05), or in 12 cell lines exhibiting no sensitizing EGFR mutations (group mCIs for gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/vinorelbine were 0.869, 0.82, and 0.853, respectively. All p values were < 0.02). The synergism could be observed in cells expressing nearly undetectable Pgp and other ABCTs tested in this study. The combination of gefitinib/gemcitabine was additive (mCI = 1.027). CONCLUSIONS:: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. Gefitinib could enhance AMTA effects through mechanisms not restricted to Pgp blockage.

AB - INTRODUCTIONS:: Although randomized clinical trials showed no benefit from combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with standard chemotherapy for advanced non-small-cell lung cancer (NSCLC), better results might be obtained by combining EGFR-TKI with individual agents that are substrates for the adenosine triphosphate binding cassette transporters (ABCTs) because EGFR-TKIs can inhibit their efflux. The combination effects deserved to be further examined in vitro. METHODS:: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. The effects of drug combinations, identified by the values of mean combination index (mCIs), were correlated with the expression levels of ABCTs. Dose-versus-log-response curves were analyzed to further evaluate the possible mechanisms of drug interactions. RESULTS:: Synergistic gefitinib/AMTA interactions were observed in the tested cell lines. The synergism was more robust in the four lines overexpressing de novo or acquired P-glycoprotein (Pgp; individual mCIs range, 0.484-0.859; all p values were < 0.05), or in 12 cell lines exhibiting no sensitizing EGFR mutations (group mCIs for gefitinib/paclitaxel, gefitinib/docetaxel, and gefitinib/vinorelbine were 0.869, 0.82, and 0.853, respectively. All p values were < 0.02). The synergism could be observed in cells expressing nearly undetectable Pgp and other ABCTs tested in this study. The combination of gefitinib/gemcitabine was additive (mCI = 1.027). CONCLUSIONS:: Combined gefitinib/AMTAs showed synergism in NSCLC cells harboring no sensitizing EGFR mutations. Gefitinib could enhance AMTA effects through mechanisms not restricted to Pgp blockage.

KW - Antimicrotubule agent

KW - Gefitinib

KW - Nonsmall-cell lung cancer

KW - P-glycoprotein

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=84863837004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863837004&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318258cf17

DO - 10.1097/JTO.0b013e318258cf17

M3 - Article

C2 - 22659964

AN - SCOPUS:84863837004

VL - 7

SP - 1218

EP - 1227

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 8

ER -